Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. Issue 8 (August 2015)

• Record Type: Journal Article
• Authors: Yoritaka, Asako; Kawajiri, Sumihiro; Yamamoto, Yorihiro; Nakahara, Toshiki; Ando, Maya; Hashimoto, Kazuhiko; Nagase, Midori; Saito, Yufuko; Hattori, Nobutaka
• Is Part Of: Parkinsonism & related disorders. Volume 21:Issue 8(2015)
• Page Start: 911
• Page End: 916
• Publication Date: 2015-08
• Subjects: Parkinson's disease -- Reduced form of coenzyme Q10 -- Randomized controlled trial -- Complex I -- Oxidative stress; Parkinson's disease -- Periodicals; Movement disorders -- Periodicals; Movement Disorders -- Periodicals; Nerve Degeneration -- Periodicals; Nervous System Diseases -- Periodicals; Parkinson Disease -- Periodicals; Tremor -- Periodicals; Parkinson, Maladie de -- Périodiques; Parkinson's disease; 616.833
• DOI: 10.1016/j.parkreldis.2015.05.022
• Languages: English
• ISSNs: 1353-8020

Abstract

Abstract: Introduction: Mitochondrial complex I deficiencies have been found in post-mortem brains of patients with Parkinson's disease (PD). Coenzyme Q10 (CoQ10 ) is the electron acceptor found in complexes I and II, and is a potent antioxidant. A recent trial of the oxidized form of CoQ10 for PD failed to show benefits; however, the reduced form of CoQ10 (ubiquinol-10) has shown better neuroprotective effects in animal models. Methods: Randomized, double-blind, placebo-controlled, parallel-group pilot trials were conducted to assess the efficacy of ubiquinol-10 in Japanese patients with PD. Participants were divided into two groups: PD experiencing wearing off (Group A), and early PD, without levodopa (with or without a dopamine agonist) (Group B). Participants took 300 mg of ubiquinol-10 or placebo per day for 48 weeks (Group A) or 96 weeks (Group B). Results: In Group A, total Unified Parkinson's Disease Rating Scale (UPDRS) scores decreased in the ubiquinol-10 group (n = 14; mean ± SD [−4.2 ± 8.2]), indicating improvement in symptoms. There was a statistically significant difference ( p < 0.05) compared with the placebo group (n = 12; 2.9 ± 8.9). In Group B, UPDRS increased in the ubiquinol-10 group (n = 14; 3.9 ± 8.0), as well as in the placebo group (n = 8; 5.1 ± 10.3). Conclusions: This is the first report showing that ubiquinol-10 may significantly improve PD with wearing off, as judged by total UPDRS scores, and that ubiquinol-10 is safe and well tolerated. Highlights: Ubiquinol-10 showed neuroprotective effects in animal models of Parkinson's disease. Randomized, controlled, trials of ubiquinol-10 were conducted in Parkinson's disease. Ubiquinol-10 was safe and well tolerated at the dose of 300 mg/day. Ubiquinol-10 showed clinical benefits in Parkinson's disease with wearing off.